Don't miss real-time top news, insights, and interviews with the experts direct from the conference floor in Chicago. Sign up now to be reminded to tune in to OncLive News Network: On Location in Chicago.

General Discussions

NCCN Guidelines for Genetic Testing in Prostate Cancer

By Emmanuel S. Antonarakis, MBBCh
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


Emmanuel S. Antonarakis, MBBCh, an associate professor of oncology at Johns Hopkins Medicine, discussed updated National Comprehensive Cancer Network (NCCN) guidelines for the genetic testing of men with prostate cancer.

Germline testing, which looks for inherited gene mutations, and somatic testing, which examines the genetic makeup of the tumor itself, can be useful in making therapy decisions. According to the NCCN, every patient with metastatic or high-risk localized non-metastatic prostate cancer should undergo germline testing. Additionally, men with lymph node metastases or distant metastases should undergo genetic testing.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.